 Home > Medical News > Latest Medical News > First-line treatment for nasopharyngeal cancer BeiGene PD-1 inhibitor combination significantly prolongs PFS in patients

First-line treatment for nasopharyngeal cancer BeiGene PD-1 inhibitor combination significantly prolongs PFS in patients

 Last Update: 2021-12-29
 Source: Internet
 Author: User

Tags

diazepam drug

nu life medical

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 10, 2021, BeiGene announced that the anti-PD-1 antibody tislelizumab combined with chemotherapy, a phase 3 clinical trial for the first-line treatment of patients with recurrent/metastatic nasopharyngeal carcinoma reached the primary endpoint

Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area and is one of the common malignant tumors of the head and neck

A total of 263 patients were enrolled in this phase 3 clinical trial.

The median PFS of the tislelizumab group was 9.

Consistent PFS benefit was observed in most patient subgroups, regardless of patient's disease status, baseline liver metastasis index, and gender

The objective response rate and complete response rate of the tislelizumab group were 69.

The combination of tislelizumab and chemotherapy showed controllable safety, consistent with the known risks of each therapeutic drug, and no new safety signals were found

Dr.

Reference materials:

[1] BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.